Lumateperone- Intra-Cellular Therapies

Drug Profile

Lumateperone- Intra-Cellular Therapies

Alternative Names: ITI-007; ITI-722

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Intra-Cellular Therapies
  • Class Antidepressants; Antipsychotics; Pyrroles; Quinoxalines; Sleep disorder therapies
  • Mechanism of Action Dopamine receptor modulators; NR2B N-Methyl D-Aspartate receptor modulators; Serotonin 2A receptor antagonists; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Behavioural disorders; Bipolar depression; Schizophrenia
  • Phase II Sleep maintenance insomnia
  • Preclinical Mental disorders
  • No development reported Mood disorders

Most Recent Events

  • 20 Nov 2017 Lumateperone- Intra-Cellular Therapies receives Fast Track designation for Schizophrenia [PO,Capsule] in USA
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Schizophrenia(In volunteers) in Europe (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Mood disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top